Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
--
Revenue (TTM)
--
Net Profit (TTM)
--
ROE
--
ROCE
--
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
EV/EBITDA
--
Div. Yield
--
Debt to Equity
--
Book Value
--
EPS
--
Face value
--
Shares outstanding
--
CFO
$9.22 Mln
EBITDA
$82.68 Mln
Net Profit
$-691.11 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
RVL Pharmaceuticals (RVLP)
| -99.8 | -57.9 | -97.8 | -99.8 | -92.5 | -80.2 | -- |
|
BSE Sensex*
| -12.2 | -5.8 | -12.6 | -1.3 | 7.5 | 8.6 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
|---|---|
|
RVL Pharmaceuticals (RVLP)
| -99.8 |
|
S&P Small-Cap 600
| 13.9 |
|
BSE Sensex
| 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas... in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. Read more
Chairman, Pres, CEO & Principal Financial Officer
Mr. Brian A. Markison
Chairman, Pres, CEO & Principal Financial Officer
Mr. Brian A. Markison
Headquarters
Bridgewater, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of RVL Pharmaceuticals plc (RVLP) is $0.00 (NASDAQ) as of 22-Dec-2023 09:30 EDT. RVL Pharmaceuticals plc (RVLP) has given a return of -92.53% in the last 3 years.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-1.95
|
1.97
|
|
2021
|
-1.06
|
1.14
|
|
2020
|
-2.92
|
2.77
|
|
2019
|
-1.34
|
3.17
|
|
2018
|
-3.18
|
0.91
|
The 52-week high and low of RVL Pharmaceuticals plc (RVLP) are Rs -- and Rs -- as of 07-Apr-2026.
RVL Pharmaceuticals plc (RVLP) has a market capitalisation of $ 3 Mln as on 22-Dec-2023. As per SEBI classification, it is a Small Cap company.
Before investing in RVL Pharmaceuticals plc (RVLP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.00
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.